17 May 2026

67 days to PCAC. ProPublica's "An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs" is institutional counter-pressure exactly in the pre-meeting window where committee members read public sentiment. Zero new RFK-aligned committee appointments. The Federal Register agenda for July 23 (BPC-157, KPV, TB-500, MOTs-C) is confirmed, with three additional peptides on July 24 per HealingMaps reporting (7 total peptides reviewed across both days). Historian: reference class for FDA bulk-substance Cat 1 votes after high-profile pre-meeting media safety coverage sits at roughly 15–25% Cat 1, below the no-media baseline of ~20–30%. The Apr 15 Cat 2 removal wave was an FDA administrative action, not a PCAC vote, and does not raise the reference-class base rate for Cat 1 conferral. Skeptic: falsifier unchanged — ≥3 RFK-aligned PCAC appointments before the July 9 advance-distribution deadline. Zero progress on this falsifier in 17 weeks. Discourse: the institutional safety frame (ProPublica + UNSW academic paper + Tucson/Wirecutter syndication on celebrity-promoted peptides) is now processing faster than the freed-peptide frame, which had peaked in mid-April. Bayesian: prior 0.55, posterior 0.55. ProPublica pressure marginally reinforces not-Cat-1 but is already priced in to the existing reference class.

Same agenda confirmation. HealingMaps reports the full 7-peptide slate spread across July 23 (the 4 we track: BPC-157, KPV, TB-500, MOTs-C) and July 24 (Semax, Epitalon, and one additional). The forecast's "at least 2 of 4 receive Cat 1 or conditional Cat 1" threshold is unchanged. The broader crowded-agenda (7 peptides in 2 days) marginally raises deferral risk on individual peptides, which cuts both ways for this forecast. Bayesian: prior 0.58, posterior 0.58.

No new launch announcement post-Q1 earnings (May 11). 24/7 Wall St "Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal" (April 20) and PeptideMaven "Set to Enter Peptide Market" continue to dominate analyst framing without a specific molecule, price, or date. The May 12 GlobeNewswire "$300 Billion peptide wellness market" forecast — combined with peptide search volume exceeding "Ozempic" — means the consumer pull is at scale. Augur: the absence of a Hims announcement at this scale of consumer demand is now itself the dominant signal. Two interpretations remain: (a) waiting for PCAC cover on July 23, (b) waiting for a smaller competitor to absorb the first regulatory scar. Both reduce the probability of a fast 2026 launch but do not change the by-year-end resolution probability. Bayesian: prior 0.84, posterior 0.84.

Material move. ProPublica published "An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs" — tier-1 institutional investigative journalism with a documented 30–90 day downstream pickup window into NYT/WaPo/CNN. The forecast's strict spec names NYT, WSJ, CNN, NPR, WaPo and does not include ProPublica directly, but ProPublica typically functions as the upstream source. Combined with: (a) NPR May 6 Medicare Bridge piece carrying GLP-1 safety framing, (b) Tucson.com / Wirecutter / AP syndication on "unapproved peptide injections promoted by influencers and celebrities," (c) UNSW April 2026 academic safety paper, (d) the ProRx LLC 15,000-vial sterility recall on compounded semaglutide and tirzepatide, the detection-channel infrastructure now has a top-tier amplifier. Historian: reference class — ephedra 2003, kratom 2018, kava 2002 — shows ProPublica-class investigations precede top-5 outlet features by 2–6 months. Forecast horizon is 11 months out, well inside the window. Skeptic: falsifier still demands NYT/WSJ/CNN/NPR/WaPo specifically; absent that, this is trajectory, not resolution. Discourse: the gray-market-influencer frame is now dominant; TikTok algorithmic suppression has begun ("Why Peptide Influencers Blocked" surfaces in TikTok Discover, a leading indicator of platform legal-risk avoidance). Bayesian: prior 0.67, posterior 0.70. +0.03 for ProPublica institutional escalation.

45 days to July 1 launch. NPR "Medicare to launch weight loss drug option in July with $50 copay" (May 6) is the most consequential mainstream-awareness signal to date. CMS confirmed Humana via LI NET infrastructure as the central processor. KFF's BALANCE Model explainer published. AMCP FAQ continues to circulate. Zepbound KwikPen only — vial and single-dose pen formulations remain excluded, which narrows the practical Zepbound patient pool (vials are the dominant tirzepatide format). The friction inventory hasn't reduced: prior authorization, step therapy, narrow drug list, single-processor model. Awareness pull up, eligibility narrowed — net flat. Bayesian: prior 0.72, posterior 0.72.

No new peptide DTC affiliate programs surfaced. GLP-1 CPA dominance ($260 vs $8–40 structural) unchanged. The $300B market forecast does not change unit economics; if anything, larger peptide DTC volumes at lower CPA reinforce the math. Bayesian: prior 0.85, posterior 0.85. compound-peptide-property-live: holds 0.85, flagged. Awaiting formal resolution row in `forecasts.tsv` per operator clarification 2026-05-15 (HRT Picks + glp1pets + Titrate iOS + /numbers satisfy the broader portfolio-property-ship interpretation). Recommend operator resolve TRUE this week and retire the narrow peptide-adjacent wording.